Skip to content
PoliticalRepoPoliticalRepo

United States · Bill · S

S. 1566 (114th)

Cancer Drug Coverage Parity Act of 2015

referredUnited States· United States Congress· EN

Introduced

11 June 2015

Last action

11 June 2015 · Introduced

Status

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Sponsors

Sen. Kirk, Mark Steven [R-IL], Sen. Franken, Al [D-MN], Sen. Vitter, David [R-LA], Sen. Cassidy, Bill [R-LA], Sen. Collins, Susan M. [R-ME], Sen. Murphy, Christopher [D-CT], Sen. Merkley, Jeff [D-OR], Sen. Gillibrand, Kirsten E. [D-NY], Sen. Brown, Sherrod [D-OH], Sen. Bennet, Michael F. [D-CO], Sen. Baldwin, Tammy [D-WI], Sen. Wicker, Roger F. [R-MS], Sen. Murkowski, Lisa [R-AK], Sen. Mikulski, Barbara A. [D-MD], Sen. Coons, Christopher A. [D-DE], Sen. Schumer, Charles E. [D-NY], Sen. Klobuchar, Amy [D-MN], Sen. Whitehouse, Sheldon [D-RI], Sen. Markey, Edward J. [D-MA], Sen. Blumenthal, Richard [D-CT], Sen. Cochran, Thad [R-MS], Sen. Warren, Elizabeth [D-MA]

Subjects

Healthcare

Source updated

5 December 2025

Healthcare

Official sourceDownload fileView documentsShare

Summary

Cancer Drug Coverage Parity Act of 2015 This bill amends the Public Health Service Act to require a group or individual health plan that covers anticancer medications administered by a health care provider to provide no less favorable coverage for anticancer medications administered by a patient. A plan may apply to patient-administered anticancer medications only the cost-sharing and limitations that apply to anticancer medications administered by a health care provider. These requirements apply to medication approved by the Food and Drug Administration that is prescribed based on a finding by the treating physician that the medication is medically necessary for cancer treatment and is clinically appropriate in terms of type, frequency, extent site, and duration. To comply with these requirements, health plans may not, for anticancer medications: (1) change or replace benefits to increase out-of-pocket costs; (2) reclassify benefits to increase costs; or (3) apply more restrictive limitations to orally administered medications than to intravenously administered or injected medications.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 11 June 2015

    Introduced

    Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

    Source: IntroReferral

  2. 11 June 2015

    Introduced

    Introduced in Senate

    Source: IntroReferral

Votes

No vote records are attached yet.

Versions

Documents

3 official files

Introduced in Senate (text)

View fileDownload file

This file cannot be previewed here. Use View or Download.

Leesvertaling

Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in Senate (text)

    Introduced in Senate · EN · 11 June 2015

    ViewDownloadOpen at official source

  • Introduced in Senate (PDF)

    Introduced in Senate · EN · 11 June 2015

    ViewDownloadOpen at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in Senate

    summary · EN · 11 June 2015

    Open at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

Related records

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.